Recent developments in weight loss pharmacotherapy have produced more evidence and options for the clinical management of obesity as a chronic disease. Clinicians will be better prepared to provide optimal care for individuals with obesity if they understand the unique effects of available and emerging weight loss medications on obesity pathophysiology and comorbid conditions and if they recognize the evolving role of pharmacotherapy relative to other interventions. This interactive program will highlight possible misconceptions about current and emerging obesity pharmacotherapies, providing participants with opportunities to vote on which statements they think are “myth” or “fact” and to receive responses from expert faculty, along with engaging roundtable discussions throughout. Faculty will elucidate the evolving role of weight loss pharmacotherapies relative to other obesity interventions, so that clinicians can appropriately employ multiple therapeutic approaches to treat obesity as a chronic disease.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the unique characteristics of current and emerging obesity pharmacotherapies in the context of obesity pathophysiology
  • Explain considerations for the use of obesity pharmacotherapies in the context of common comorbid conditions
  • Discuss the evolving role of obesity pharmacotherapy in the context of other obesity-management approaches
  • Explore how emerging pharmacotherapies for inherited obesity disorders might further the understanding of obesity pathophysiology and the development of obesity interventions

Accreditation Statement


The Institute for Medical and Nursing Education, Inc. (IMNE) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

IMNE designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses/Nurse Practitioners

IMNE is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC’s) Commission on Accreditation.

IMNE designates this educational activity for 1.50 contact hours of continuing education credit (0.15 CEUs). Accreditation by the ANCC’s Commission on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product. IMNE has determined that 1.25 hours of this program will satisfy ANCC’s pharmacotherapeutics contact hour requirement for ANCC certified Clinical Nurse Specialists and Nurse Practitioners. The CEU certificate will reflect this credit.

Certified Diabetes Educators

ANCC-accredited providers have been approved by the National Certification Board for Diabetes Educators (NCBDE) as providers of continuing education (CE). Individuals seeking recertification from the NCBDE can use the CE contact hours received through participation in this activity.

Registration link coming soon.

Sponsored by The Institute of Medical and Nursing Education, Inc.

Supported by an educational grant from Novo Nordisk Inc.